At early drug discovery, purified protein-based assays are often used to characterise compound potency. As far as dose response is concerned, it is often thought that a time-independent inhibitor is reversible and a time-dependent inhibitor is irreversible. Using a simple kinetics model, we investigate the legitimacy of this. Our model-based analytical analysis and numerical studies reveal that dose response of an irreversible inhibitor may appear time-independent under certain parametric conditions. Hence, time-independence cannot be used as evidence for inhibitor reversibility. Furthermore, we also analysed how the synthesis and degradation of a target receptor affect drug inhibition in an in vitro cell-based assay setting. Indeed, these ...
During drug discovery, assessment of in vivo target occupancy by therapeutic candidates is often req...
The hyperbolic parabola is commonly used to summarize kinetics for enzyme reactions and receptor bin...
The pharmacodynamics of drug-candidates is often optimized by metrics that describe target binding (...
At early drug discovery, purified protein-based assays are often used to characterise compound poten...
At early drug discovery, purified protein-based assays are often used to characterise compound poten...
The potential of enzyme inhibition of a drug is frequently quantified in terms of IC50 values. While...
Reproducibility of biological data is a significant problem in research today. One potential contrib...
Binding kinetics is closely related to the efficacy of drugs. Several aspects of binding kinetics, s...
The Michaelis–Menten model of enzyme kinetic assumes the free ligand approximation, the steady-state...
A difficulty associated with high throughput screening for enzyme inhibitors is to establish reactio...
AbstractThe kinetics of complexing inactivation at identical enzyme and inhibitor concentrations wer...
<div><p>A difficulty associated with high throughput screening for enzyme inhibitors is to establish...
INTRODUCTION\nDrug-target binding kinetics are major determinants of the time course of drug actio...
Abstract: Targeting receptor systems by competitive inhibition is the objective of various antibody ...
Covalent inhibition has become more accepted in the past two decades, as illustrated by the clinical...
During drug discovery, assessment of in vivo target occupancy by therapeutic candidates is often req...
The hyperbolic parabola is commonly used to summarize kinetics for enzyme reactions and receptor bin...
The pharmacodynamics of drug-candidates is often optimized by metrics that describe target binding (...
At early drug discovery, purified protein-based assays are often used to characterise compound poten...
At early drug discovery, purified protein-based assays are often used to characterise compound poten...
The potential of enzyme inhibition of a drug is frequently quantified in terms of IC50 values. While...
Reproducibility of biological data is a significant problem in research today. One potential contrib...
Binding kinetics is closely related to the efficacy of drugs. Several aspects of binding kinetics, s...
The Michaelis–Menten model of enzyme kinetic assumes the free ligand approximation, the steady-state...
A difficulty associated with high throughput screening for enzyme inhibitors is to establish reactio...
AbstractThe kinetics of complexing inactivation at identical enzyme and inhibitor concentrations wer...
<div><p>A difficulty associated with high throughput screening for enzyme inhibitors is to establish...
INTRODUCTION\nDrug-target binding kinetics are major determinants of the time course of drug actio...
Abstract: Targeting receptor systems by competitive inhibition is the objective of various antibody ...
Covalent inhibition has become more accepted in the past two decades, as illustrated by the clinical...
During drug discovery, assessment of in vivo target occupancy by therapeutic candidates is often req...
The hyperbolic parabola is commonly used to summarize kinetics for enzyme reactions and receptor bin...
The pharmacodynamics of drug-candidates is often optimized by metrics that describe target binding (...